Durable complete response to immunotherapy with anti-PD-1 antibody nivolumab in a patient with oral squamous cell carcinoma presenting with lung metastasis: A case report

Katsuhisa Sekido; Shuichi Imaue; Kei Tomihara; Hidetake Tachinami; Kentaro Yamagishi; Seisuke Okazawa; Atsushi Ikeda; Kumiko Fujiwara; Makoto Noguchi

doi:10.1002/ccr3.4545

Durable complete response to immunotherapy with anti-PD-1 antibody nivolumab in a patient with oral squamous cell carcinoma presenting with lung metastasis: A case report

Clin Case Rep. 2021 Aug 30;9(9):e04545. doi: 10.1002/ccr3.4545. eCollection 2021 Sep.

Authors

Katsuhisa Sekido^{1

2}, Shuichi Imaue¹, Kei Tomihara¹, Hidetake Tachinami¹, Kentaro Yamagishi³, Seisuke Okazawa⁴, Atsushi Ikeda¹, Kumiko Fujiwara¹, Makoto Noguchi¹

Affiliations

¹ Department of Oral and Maxillofacial Surgery Faculty of Medicine University of Toyama Toyama City Japan.
² Department of Oral and Maxillofacial Surgery Toyama Red Cross Hospital Toyama City Japan.
³ Department of Radiology Faculty of Medicine University of Toyama Toyama City Japan.
⁴ First Department of Internal Medicine Faculty of Medicine University of Toyama Toyama City Japan.

Abstract

Although the optimal treatment method for metastatic oral cancer remains largely unknown, the present case suggests that immunotherapy is a potentially promising alternative for metastatic oral cancer in which other therapies are no longer effective.

Keywords: anti‐PD‐1; complete remission; immune checkpoint inhibitor; lung metastasis; nivolumab; oral squamous cell carcinoma.

Publication types

Case Reports